Payment overview · 2025
General Payments
$450.15
34 reported records · 7 companies
Healthcare provider profile · identity verified
Jean Jacques Saunders, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PRAIRIEVILLE, LA · NPI 1396735270
Verified facts
What the public records show
CMS Open Payments records show Jean Jacques Saunders, M.D. received $450.15 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.24 | 36.7% | 20 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.80 | 18.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.45 | 16.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.55 | 13.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.81 | 7.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.96 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.34 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $450.15 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.30 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $83.80 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.94 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $72.45 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.02 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $59.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
245 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 643 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 547 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 100 |
| Gabapentin | Gabapentin | 415 | 86 |
| Trazodone Hcl | Trazodone Hcl | 413 | 82 |
| Alprazolam | Alprazolam | 383 | 68 |
| Omeprazole | Omeprazole | 370 | 93 |
| Meloxicam | Meloxicam | 331 | 72 |
| Losartan Potassium | Losartan Potassium | 320 | 88 |
| Sertraline Hcl | Sertraline Hcl | 273 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 59 |
| Mounjaro | Tirzepatide | 245 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 81 |
| Lisinopril | Lisinopril | 239 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 59 |
| Furosemide | Furosemide | 213 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 40 |
| Bupropion Xl | Bupropion Hcl | 210 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 201 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 169 | 32 |
| Ozempic | Semaglutide | 167 | 30 |
| Potassium Chloride | Potassium Chloride | 167 | 37 |
| Metformin Hcl | Metformin Hcl | 166 | 53 |
| Temazepam | Temazepam | 158 | 24 |
| Tramadol Hcl | Tramadol Hcl | 152 | 29 |
| Clonazepam | Clonazepam | 144 | 24 |
| Simvastatin | Simvastatin | 142 | 30 |
| Montelukast Sodium | Montelukast Sodium | 133 | 30 |
| Atenolol | Atenolol | 130 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 130 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 28 |
| Metformin Hcl Er | Metformin Hcl | 121 | 32 |
| Lorazepam | Lorazepam | 117 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 22 |
| Glipizide Er | Glipizide | 114 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 30 |
| Famotidine | Famotidine | 113 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 113 | 22 |
| Diazepam | Diazepam | 107 | 13 |
| Ezetimibe | Ezetimibe | 103 | 27 |
| Mirtazapine | Mirtazapine | 102 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 25 |
| Fenofibrate | Fenofibrate | 101 | 21 |
| Celecoxib | Celecoxib | 93 | 21 |
| Prednisone | Prednisone | 93 | 63 |
| Buspirone Hcl | Buspirone Hcl | 91 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 23 |
| Donepezil Hcl | Donepezil Hcl | 89 | 22 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 88 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 67 |
| Ondansetron Odt | Ondansetron | 86 | 37 |
| Allopurinol | Allopurinol | 85 | 22 |
| Carvedilol | Carvedilol | 85 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 18 |
| Jardiance | Empagliflozin | 82 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 79 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 62 |
| Eliquis | Apixaban | 72 | 17 |
| Methocarbamol | Methocarbamol | 72 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 72 | 23 |
| Linzess | Linaclotide | 70 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 16 |
| Glipizide | Glipizide | 64 | 15 |
| Doxepin Hcl | Doxepin Hcl | 63 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Glimepiride | Glimepiride | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 15 |
| Fluconazole | Fluconazole | 56 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 19 |
| Estradiol | Estradiol | 54 | suppressed |
| Olanzapine | Olanzapine | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 13 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Lovastatin | Lovastatin | 48 | 13 |
| Pregabalin | Pregabalin | 48 | 11 |
| Promethazine Hcl | Promethazine Hcl | 48 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 14 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 41 | 16 |
| Mupirocin | Mupirocin | 40 | 29 |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Valacyclovir | Valacyclovir Hcl | 39 | 19 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Desloratadine | Desloratadine | 37 | 12 |
| Nystatin | Nystatin | 37 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 15 |
| Sucralfate | Sucralfate | 33 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Valsartan | Valsartan | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Zaleplon | Zaleplon | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Azithromycin | Azithromycin | 17 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $450.15 · 34 records | ABBVIE INC. | Auvelity, FREESTYLE LIBRE 3, JARDIANCE, Korlym, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error